Yngve joined NDA in 2021 and excels at advising companies on their development strategies identifying the optimal connection between products and market, facilitating the generation of evidence essential for market access and price optimization and communication of product value to stakeholders.
Key Areas Of Expertise
- HTA Expert including Real-World Evidence, Market Access and Health economics
- Profound experience in clinical development and medical affairs covering various therapeutic areas
- In-depth expertise in Pharmaceutical medicinal products including ATMPs, Radiopharmaceuticals as well as Medical Device
- Highly qualified management experience as executive VP, CMO and from senior management roles in healthcare and industry.
Before Joining The NDA Advisory Board
Yngve served as executive vice president at LINK Medical Research focusing on early and late phase clinical development, real-world evidence, market access & health economics, and medical device. He has experience from 50+ HTAs within various pharmaceuticals, biotechnology, and medical devices across different therapeutic areas. Yngve has 10+ years of pharmaceutical development and medical affairs experience from Pfizer and Biogen.
Yngve is a certified clinical specialist in anaesthesiology and holds a Master of Management degree from the Norwegian Business School, a Doctor of Business Administration from Cranfield University Master of Science in health economics, policy and management from the London School of Economics.
Rafael A. Leiva, Bente M. Bergersen, Ane-Kristine Finbrå ten, Per Kristian Sandvei, Oystein Simonsen, Carola M. Rosseland, Lital Young, Yngve Mikkelsen, Ravinder Singh, Olav Dalgard; Real-world effectiveness of elbasvir/grazoprevir in the treatment of patients with hepatitis C virus genotype 1a infection in Norway. Submitted EASL, 2020, London, UK.
Ristun C, Bjornstad B, Hestvik ALK, Myhr KM, Mikkelsen Y; Budget impact of the introduction of alemtuzumab in Norway; a real-world evidence analysis using data from the Norwegian Patient Registry, the Norwegian Prescription Database, and IMS sales data. 2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Heggelund L, Singh R, Aballi S, Rosseland CM, Mikkelsen Y, Damå s J K; Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database. Oral presentation. 17th European AIDS Conference, November 6-9, 2019 Basel, Switzerland.
Karlsen LN, Ulstein K, Mikkelsen Y, Rosseland CM, Singh R, Dalgard O; Retrospective analysis of co-medication patterns among patients treated for HCV, and potential interactions with antiviral treatment, in Norway during 2014-2017 using the Norwegian population-based prescription database. HIV & Hepatitis Nordic Conference, September 2019, Stockholm, Sweden.
Bjork MH, Dueland AN, Soraard F, Mikkelsen Y; The NorMig study: Migraine prophylactics in the Norwegian population- duration of use and effect on triptan prescription. Oral Presentation EAN, Oslo, 2019
Bjork MH, Dueland AN, Soraard F, Mikkelsen Y; Kartlegging av bruk av forebyggende medisiner for migrene i Norge 2009-2017. Oral presentation Nevrodagene 13. March 2018, Oslo.
Mikkelsen Y; Understanding physicians’ conception of quality of health care delivery- an explorative study using the repertory grid technique. 2018-11, Ispor Europe 2018, Barcelona, Spain, Value in Health, vol. 21, s3 (October 2018)